MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-08-2026
Pacific Biosciences of California Long-Term Debt 2011-2026 | PACB
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Pacific Biosciences of California
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.6 M | 14.9 M | 31.6 M | 897 M | 50 M | 37.7 M | 15.9 M | 14.7 M | 13.6 M | 16.1 M | 14.9 M | 14.1 M | 13.3 M | - | - | 2.93 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 897 M | 2.93 M | 85.2 M |
Quarterly Long-Term Debt Pacific Biosciences of California
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 M | 54.3 M | 52.1 M | 50.5 M | 14.9 M | - | - | 29 M | 31.6 M | 34.1 M | 36.6 M | 897 M | 41.1 M | 897 M | 896 M | 896 M | 896 M | 896 M | 896 M | 896 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 15.9 M | 15.5 M | 15.2 M | 14.9 M | 14.7 M | 14.4 M | 14.1 M | 13.9 M | 13.6 M | - | - | - | 16.1 M | - | - | - | - | - | - | - | 14.1 M | - | - | - | 13.3 M | - | - | 2.56 M | 2.61 M | 2.66 M | 2.7 M | 2.75 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 897 M | 2.56 M | 184 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
307 K | - | - | $ 1.31 B | USA |
 |
Fulgent Genetics
FLGT
|
360 K | $ 19.5 | 7.5 % | $ 600 M | USA |
 |
Celcuity
CELC
|
138 M | $ 92.47 | 3.96 % | $ 4.32 B | USA |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
574 K | $ 5.76 | 11.41 % | $ 7.66 M | USA |
 |
Castle Biosciences
CSTL
|
9.64 M | $ 21.6 | 5.93 % | $ 626 M | USA |
 |
Aspira Women's Health
AWH
|
1.04 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
30 K | - | -61.36 % | $ 2.46 M | USA |
 |
Guardant Health
GH
|
1.5 B | $ 133.06 | 4.75 % | $ 16.7 B | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
ICON Public Limited Company
ICLR
|
2.87 B | $ 152.8 | 6.18 % | $ 12 B |  Irlanda |
 |
CareDx, Inc
CDNA
|
19.7 M | $ 23.12 | 3.63 % | $ 1.23 B | USA |
 |
Illumina
ILMN
|
486 M | $ 168.06 | -1.68 % | $ 26 B | USA |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
752 K | $ 1.79 | 2.29 % | $ 7.92 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
546 K | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
22.9 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
Mettler-Toledo International
MTD
|
2.09 B | - | - | $ 24.3 B |  Schweiz |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
569 M | - | - | $ 6.94 B | USA |
 |
NeoGenomics
NEO
|
342 M | $ 11.31 | 11.54 % | $ 1.45 B | USA |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 185.79 | 3.29 % | $ 9.21 B | USA |
 |
Natera
NTRA
|
118 M | $ 222.1 | 4.84 % | $ 30.4 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
114 M | $ 458.69 | 1.75 % | $ 13.2 B | USA |
 |
Exact Sciences Corporation
EXAS
|
6.4 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
75 M | $ 19.75 | 3.73 % | $ 442 M | USA |
 |
Myriad Genetics
MYGN
|
120 M | $ 4.69 | 6.59 % | $ 434 M | USA |
 |
Personalis
PSNL
|
621 K | $ 12.1 | 12.24 % | $ 1.08 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
5.7 B | $ 25.99 | 2.52 % | $ 24.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
35.6 M | $ 7.01 | 4.32 % | $ 293 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.65 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
49.9 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
100 K | - | - | $ 4.94 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 260.97 | 0.79 % | $ 21.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
61.8 M | - | - | $ 4.42 B | USA |
 |
Thermo Fisher Scientific
TMO
|
39.2 B | $ 482.03 | 1.7 % | $ 182 B | USA |
 |
Trinity Biotech plc
TRIB
|
82.7 M | $ 0.68 | -2.4 % | $ 244 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
875 M | $ 9.12 | 3.52 % | $ 1.98 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 196.12 | 1.27 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
947 M | $ 376.47 | -0.87 % | $ 22.4 B | USA |